0001104659-24-026040.txt : 20240221
0001104659-24-026040.hdr.sgml : 20240221
20240221161656
ACCESSION NUMBER: 0001104659-24-026040
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240215
FILED AS OF DATE: 20240221
DATE AS OF CHANGE: 20240221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ben-Kiki Tomer
CENTRAL INDEX KEY: 0002011990
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37704
FILM NUMBER: 24659716
MAIL ADDRESS:
STREET 1: C/O DARIOHEALTH CORP.
STREET 2: 322 W 57TH ST. #33B
CITY: NEW YORK
STATE: NY
ZIP: 10019
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: DarioHealth Corp.
CENTRAL INDEX KEY: 0001533998
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 452973162
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 322 W 57TH ST. #33B
CITY: NEW YORK
STATE: NY
ZIP: 10019
BUSINESS PHONE: 972-4-770-6377
MAIL ADDRESS:
STREET 1: 322 W 57TH ST. #33B
CITY: NEW YORK
STATE: NY
ZIP: 10019
FORMER COMPANY:
FORMER CONFORMED NAME: LabStyle Innovations Corp.
DATE OF NAME CHANGE: 20111101
4
1
tm246888-2_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-02-15
0
0001533998
DarioHealth Corp.
DRIO
0002011990
Ben-Kiki Tomer
122 W 57TH ST, #33B
NEW YORK
NY
10019
0
1
0
0
Chief Operating Officer
0
Stock Option (right to buy)
2.55
2024-02-15
4
A
0
717947
0
A
2034-02-15
Common Stock
717947
717947
D
Stock Option (right to buy)
2.55
2024-02-15
4
A
0
300000
0
A
2034-02-15
Common Stock
300000
300000
D
The options vest as follows: 291,742 shares vest immediately, and the remaining 426,205 shares vest over two years in eight equal quarterly amounts, subject to subject to the Reporting Person's continued services to the Issuer on the applicable vesting date.
The options vest immediately upon achieving certain milestones relating to the achievement of revenues (on a U.S. generally accepted account principals basis) for the year ending December 31, 2024, the achievement of certain operating expense targets for the years ending December 31, 2024 and December 31, 2025, the ability to generate software value from funds invested and meet product roadmap and the retention of key employees post transaction, subject in each case to the Reporting Person's continued services to the Issuer on the applicable vesting date.
/s/ Tomer Ben-Kiki
2024-02-21